Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 4
2011 1
2014 2
2015 3
2016 3
2017 9
2018 1
2019 3
2020 7
2021 7
2022 7
2023 4
2024 4
2025 13
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Metacognitive mechanisms underlying lucid dreaming.
Filevich E, Dresler M, Brick TR, Kühn S. Filevich E, et al. Among authors: brick tr. J Neurosci. 2015 Jan 21;35(3):1082-8. doi: 10.1523/JNEUROSCI.3342-14.2015. J Neurosci. 2015. PMID: 25609624 Free PMC article.
Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with OUD: a randomized, double-blind, placebo-controlled clinical trial protocol.
Freet CS, Shuler K, Kawasaki S, Weintraub E, Greenblatt A, Kladney M, Nunes E, Foster KL, Kong L, Raja-Khan N, Cleveland HH, Grigson PS, Bunce SC, Brick TR, Nyland JE. Freet CS, et al. Among authors: brick tr. Addict Sci Clin Pract. 2025 Oct 30;20(1):89. doi: 10.1186/s13722-025-00618-2. Addict Sci Clin Pract. 2025. PMID: 41168808 Free PMC article.
Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with treatment-refractory OUD: A randomized, double-blind, placebo-controlled clinical trial protocol.
Freet CS, Shuler K, Kawasaki S, Weintraub E, Greenblatt A, Kladney M, Nunes E, Foster KL, Kong L, Raja-Khan N, Cleveland HH, Grigson PS, Bunce SC, Brick TR, Nyland JE. Freet CS, et al. Among authors: brick tr. Res Sq [Preprint]. 2025 May 26:rs.3.rs-6666196. doi: 10.21203/rs.3.rs-6666196/v1. Res Sq. 2025. Update in: Addict Sci Clin Pract. 2025 Oct 30;20(1):89. doi: 10.1186/s13722-025-00618-2. PMID: 40502777 Free PMC article. Updated. Preprint.
Maintained Individual Data Distributed Likelihood Estimation (MIDDLE).
Boker SM, Brick TR, Pritikin JN, Wang Y, von Oertzen T, Brown D, Lach J, Estabrook R, Hunter MD, Maes HH, Neale MC. Boker SM, et al. Among authors: brick tr. Multivariate Behav Res. 2015;50(6):706-20. doi: 10.1080/00273171.2015.1094387. Multivariate Behav Res. 2015. PMID: 26717128 Free PMC article.
OpenMx 2.0: Extended Structural Equation and Statistical Modeling.
Neale MC, Hunter MD, Pritikin JN, Zahery M, Brick TR, Kirkpatrick RM, Estabrook R, Bates TC, Maes HH, Boker SM. Neale MC, et al. Among authors: brick tr. Psychometrika. 2016 Jun;81(2):535-49. doi: 10.1007/s11336-014-9435-8. Epub 2015 Jan 27. Psychometrika. 2016. PMID: 25622929 Free PMC article.
The ILHBN: challenges, opportunities, and solutions from harmonizing data under heterogeneous study designs, target populations, and measurement protocols.
Chow SM, Nahum-Shani I, Baker JT, Spruijt-Metz D, Allen NB, Auerbach RP, Dunton GF, Friedman NP, Intille SS, Klasnja P, Marlin B, Nock MK, Rauch SL, Pavel M, Vrieze S, Wetter DW, Kleiman EM, Brick TR, Perry H, Wolff-Hughes DL; Intensive Longitudinal Health Behavior Network (ILHBN). Chow SM, et al. Among authors: brick tr. Transl Behav Med. 2023 Jan 20;13(1):7-16. doi: 10.1093/tbm/ibac069. Transl Behav Med. 2023. PMID: 36416389 Free PMC article.
60 results